Search

Aldesleukin

This recombinant form differs from native interleukin-2 in the following ways: a) Aldesleukin is not glycosylated because it is derived from E. coli; b) the molecule has no N-terminal alanine; the codon … Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene.

Colistin

It is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes.

Turoctocog alfa

[A31504] It was developped by Novo Nordisk and FDA approved in October 16, 2013.[L1104] … Turoctocog alfa is produced in Chinese hamster ovary (CHO) cells without addition of any human- or animal-derived materials.

Pipotiazine

Pipotiazine has actions similar to those of other phenothiazines. Among the different phenothiazine derivatives, it appears to be less sedating and to have a weak propensity for causing hypotension or potentiating the effects of CNS depr...

Daclizumab

in de novo allogeneic renal transplantation and used concomitantly with an immunosuppressive regimen like cyclosporine and corticosteroids in patients who are not hight immunized, for commercial reasons … The human sequences were derived from the constant domains of human IgG1 and the variable framework regions of the Eu myeloma antibody.

Sinapultide

[L2504] Windtree is currently developing aerosolized KL4 surfactant to treat RDS in premature infants, and thereafter, to potentially address a range of indications in neonatal, pediatric and adult … [L2502] Windtree Therapeutics plans a phase III trial for Respiratory distress syndrome in 2018.

Rose bengal I-131

Gemfibrozil

[L8525] Gemfibrozil was granted FDA approval on 21 December 1981.[L8525]

Levobetaxolol

Levobetaxolol is a beta-blocker used to lower the pressure in the eye to treat conditions such as glaucoma.

Olaratumab

Studies show that the treatment of olaratumab in combination with doxorubicin resulted in significant reduction of cancer cell proliferation and tumor growth. … Olaratumab was granted accelerated approval (as Lartruvo) as initial therapy to treat adults with certain types of soft tissue sarcoma (STS) in October, 2016.